Description: Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.
Home Page: www.celadonpharma.co.uk
CEL Technical Analysis
32-33 Cowcross Street
London,
EC1M 6DF
United Kingdom
Phone:
44 20 3150 0252
Officers
| Name | Title |
|---|---|
| Mr. James Short | CEO & Director |
| Ms. Kathleen Joy Long BCOMM, CA | CFO & Director |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5108 |
| Price-to-Sales TTM: | 3040.2153 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |